Abstract
The dismal prognosis of glioblastoma had remained unchanged for the past 30 years until the association of temozolomide and radiotherapy in the breakthrough European Organization for Cancer/National Cancer Institute of Canada (EORTC/NCIC) trial brought new hope for patients. This trial will serve as a platform for new and exciting clinical and translational research areas. We review here the role of standard radiotherapy and chemotherapy in glioblastoma and the potential causes of their failure, and we focus on some of the aspects that led to the successful EORTC/NCIC trial and some of the related studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Curran WJ, Scott JB, Horton J, et al.: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85:704–710. A very important paper that enabled the creation of prognostic classes in glioblastoma, which proved to be an invaluable tool for analyzing results and for decision making.
Laperriere N, Zuraw L, Cairncross G, et al.: Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002, 64:259–273. An excellent article summarizing evidence-based medicine for the use of radiotherapy in glioblastoma.
Gonzalez DG, Menten J, Bosch DA, et al.: Accelerated radiotherapy in glioblastoma multiforme: a dose-searching prospective study. Radiother Oncol 1994, 32:98–105.
Miralbell R, Mornex F, Greiner R, et al.: Accelerated radiotherapy, carbogen and nicotinamide in glioblastoma multiforme: report of the European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol 1999, 17:3143–3149.
Glioma Meta-analysis Trialists Group: Chemotherapy in adult high-grade glioma: a systematic review and metaanalysis of individual patient data from 12 randomized trials. Lancet 2002, 359:1011–1018. This meta-analysis sums up nitrosourea-based and radiotherapy trials in glioblastoma, which served as the former base for standard treatment.
Durando X, Lemaire JJ, Tortochaux J, et al.: High dose BCNU followed by autologous hematopoeitic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant 2003, 31:559–564.
Qureshi AI, Suri MF, Khan J, et al.: Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures. J Neuroncol 2001, 51:151–158.
Yung WK, Prados MD, Yaya-Tur R: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytomas or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999, 17:2762–2771.
Yung WK, Albright RE, Olson J, et al.: A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588–593. s study was an important platform for further clinical trials of emozolomide in glioblastoma
Wedge SR, Porteous JK, Glaser MG, et al.: In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997, 8:92–97.
Van Rijn J, Heimans JJ, Van den Berg J, et al.: Survival of human glioma cells treated with various combinations of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000, 47:779–784.
Wick W, Wick A, Schulz JB, et al.: Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 2002, 62:1915–1919.
Stupp R, Dietrich PY, Ostermann Kraljevic S, et al.: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375–1382. This phase II study of concomitant and adjuvant temozolomide and radiotherapy demonstrated very encouraging results and served as the experimental arm of the pivotal EORTC/NCIC temozolomide randomized trial.
Stupp R, Mason WP, Van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987–996. The first study in 30 years to demonstrate a statistically significant and clinically meaningful improvement in survival in glioblastoma by the addition of concomitant and adjuvant temozolomide to radiotherapy.
Hegi ME, Diserens AC, Gorlia T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997–1003. A very important translational research work associated with the EORTC/NCIC trial, wherein it was demonstrated that the "silencing", or methylation of MGMT, a repair enzyme gene, was associated with a better prognosis and was predictive for response for temozolomide and radiotherapy.
Athanassiou H, Synodinou M, Maragoudakis E, et al.: Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005, 23:2372–2377. A study similar to EORTC/NCIC in design, which confirms—on a smaller scale—the superiority of temozolomide plus radiotherapy over radiotherapy alone in glioblastoma.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mirimanoff, RO. The evolution of chemoradiation for glioblastoma: A modern success story. Curr Oncol Rep 8, 50–53 (2006). https://doi.org/10.1007/s11912-006-0009-5
Issue Date:
DOI: https://doi.org/10.1007/s11912-006-0009-5